Clinical trial NCT06248112: Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
Official title: A Bioequivalence Study of Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets in Healthy Thai Volunteers Under Fasting Condition
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: Healthy Subjects
Keywords: Bioequivalence Sacubitril 97 mg and Valsartan 103 mg film-coated tablets
Lead sponsor: Bio-innova Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-02-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: The study is to compare the rate and extent of absorption of a generic formulation with that of a reference for mulation when given as equal labeled dose. The study will be a randomized, open-label, single oral dose, full replicated crossover design with four-period, two-treatment, and two-sequence under fasting condition and at least 14 days washout period between the doses.

Detailed description: Title A Bioequivalence study of a randomized, open-label, single oral dose, full replicated crossover design with four-period, two-treatment, and two-sequence of Sacubitril 97 mg and Valsartan 103 mg film-coated tablets relative to Entresto 97 mg/103 mg film-coated tablets in healthy Thai volunteers under fasting condition.

Objectives The primary objective is to compare the rate and extent of absorption of a generic formulation with that of a reference formulation when given as equal labeled dose. The secondary objective is to evaluate the safety after oral administration of both test and reference formulation in healthy Thai volunteers.

Study Design Randomized, open-label, single dose, fully replicate crossover design with four-period, two-treatment and two-sequence under fasting condition and at least 7 days washout period between the doses.

Sample Size 40 Healthy Human Thai subjects. Four extra subjects if available, may be checked-in on the day of check in of period-I to compensate for any dropout prior to dosing of period-I. These subjects will be dosed if there are dropouts prior to dosing in period-I. If there are no dropouts, these subjects will be checked-out without being dosed after completion of dosing in period-I.

Drug-Product Test-Product: Sacubitril 97 mg and Valsartan 103 mg film-coated tablets Reference-product: ENTRESTOTM (Film-Coated Tablets) 97/103 mg Manufactured by: Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd., Singapore for Novartis Pharma AG, Basle, Switzerland

Administration After an overnight fasting at clinical facility of at least 10 hours, each volunteer will receive a single dose of Sacubitril 97 mg and Valsartan 103 mg film-coated tablets of either test or reference with 250 mL of drinking water. Each volunteer will be allowed to drink water as desire except 1 hour before and after drug administration. The formulation is given in a full replication crossover fashion as per the randomization schedule. After the administration, the subject's oral cavity will be checked by using flashlight to confirm complete medication and fluid consumption by pharmacist.

Blood Schedule In each period, a total of 24 blood samples (approximately 7 mL each) will be collected pre-dose (0.000 hour) and at 0.083, 0.167, 0.333, 0.500, 0.670, 0.830, 1.000, 1.330, 1.670, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 8.000, 10.000, 12.000, 16.000, 24.000, 36.000 and 48.000 hours after study drug administration, respectively. The sample collection at 36.000 and 48.000 hours after dosing will be on ambulatory basis (i.e. on separate visit).

Sample Collection Blood samples will be collected through an indwelling catheter placed in a vein using disposable syringe or through fresh venipuncture with disposable syringes and needles. Approximately 7 mL blood sample will be withdrawn and transferred to sample collection pre-labeled tubes containing K3EDTA as anticoagulant at each sampling time point. After collection of blood samples from each subject at each time point, samples will be centrifuged at 4000 rpm for 5 minutes at 4±2°C. After centrifugation, the plasma samples will be aliquot into four pre-labeled cryovials, separating into two for sacubitril and two for valsartan (with "O" Original and "D" Duplicate label). The original cryovials for each molecule will be filled with approximately 1 mL of plasma, leaving the remaining volume for the duplicate cryovials. Cryovials containing plasma sample will be stored at -70±10 °C.

Analytical Method Sacubitril and Valsartan plasma concentration will be assayed as per Thai TFDA requirements/ international Guidelines/In-house SOP by using a UPLC-MS/MS method

Pharmacokinetic Parameters Primary pharmacokinetic parameter: Cmax, AUC0→t and AUC0→∞ and secondary pharmacokinetic parameter: Tmax, T1/2, Kel, AUC0→t/AUC0→∞ will be determined from the plasma concentration data of analytes.

Statistical Analysis ANOVA, two one-sided tests for bioequivalence, for log-transformed pharmacokinetic parameters Cmax, AUC0→t and AUC0→∞ will be performed.

Acceptance Criteria for Bioequivalence To be considered as bioequivalent For AUC: The 90% CI for the ratio of AUC0→t and AUC0→∞ of Sacubitril and Valsartan from test and reference products on the log-transformed data should be between 80.00-125.00%.

For Cmax:

The 90% CI for the ratio of Cmax of Sacubitril and Valsartan from test and reference products on the log-transformed data should be in the acceptance criteria based on the within-subject variability of reference product (ISCV) seen in the study using scaled-average-bioequivalence as recommended in the 2010 EMA guideline. if ISCV\>30% for reference product in the study, then

1. 90% Confidence Interval for the ratio of Cmax should be within widened acceptance range\*\*
2. The geometric mean ratio (GMR) of Test and Reference should be 80.00-125.00% if ISCV\<30% for reference product in the study, then 90% Confidence Interval for the ratio of Cmax should be within 80.00-125.00%

   * Widening of Acceptance Range for Cmax:

The extent of the widening is defined based upon the within-subject variability obtained in the bioequivalence study using scaled-average-bioequivalence according to \[U, L\] = exp \[±k·SWR\], where U is the upper limit of the acceptance range, L is the lower limit of the acceptance range, k is the regulatory constant set to 0.760 and SWR is the within-subject standard deviation of the log-transformed values of Cmax of the Reference product.

Acceptance criteria for Cmax can be widened to a maximum of 69.84 - 143.19%, if within-subject variability of reference product for Ln- transformed Cmax ≥ 50%

Eligibility criteria: Inclusion Criteria:

1. Willingness to provide written informed consent prior to participate in the study.
2. Healthy Thai subjects are between 18 to 55 years of age.
3. The Body Mass Index (BMI) ranges from 18.5 to 30 kg/m2.
4. Comprehensive of the nature and purpose of the study and compliance with the requirement of the entire protocol and allow investigators to draw 7 mL of blood for monitoring subjects' safety after the completion of the study.
5. Negative urine pregnancy test for women and no breast-feeding.
6. Absence of significant diseases or clinically significant abnormal laboratory values on the laboratory evaluations, medical history or surgery during the screening. Some of the laboratory values e.g. Complete blood count etc. that out of the normal range will be carefully considered by physician.

Exclusion Criteria:

1. History or evidence of allergy or hypersensitivity to Sacubitril/Valsartan or any related drugs or any of the excipients of this product.
2. Subject with B.P. is Systolic B.P \< 100, ≥140 mm/Hg, Diastolic B.P \< 70, ≥90 mm/Hg or pulse rate \> 100 beats per minute.
3. Serum bilirubin greater than 1.5 times the upper limit of reference range (ULRR).\*
4. Serum creatinine greater than 1.5 times the upper limit of reference range (ULRR).\*
5. Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2 times the upper limit of reference range (ULRR).\*
6. Positive of hepatitis B or C virus.
7. Have more than one abnormal EKG, which is considered as clinically significant.\*
8. History or evidence of angioedema related to previous ACE inhibitor or ARB therapy.
9. History or evidence of heart, renal, hepatic disease, pulmonary obstructive disease, bronchial asthma, hypertension or glaucoma.
10. History or evidence of gastrointestinal disorder likely to influence drug absorption or previous GI surgery other than appendectomy.
11. Any major illness in the past 3 months or any significant ongoing chronic medical illness.
12. History of psychiatric disorder.
13. History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
14. History of usually smoking (more than 10 cigarettes per day within past 1 year), if moderate smokers (less than 10 cigarettes per day) cannot stop at least 7 days before the study drug administration and until the completion of the study.
15. High caffeine consumption (more than 5 cups of coffee or tea per day) and cannot stop at least 2 days before the study drug administration and until the completion of each period of the study.
16. Potassium rich food consumption (e.g. banana, orange, avocado, spinach, et al) at least 2 days before the study drug administration and until the completion of each period of the study.
17. Positive drug abused test in urine (Benzodiazepines, Marijuana (THC), Methamphetamine, Cocaine and Opioids).
18. Receipt of any prescription drug therapy within 14 days or 5 half-lives (whichever longer) preceding the first dose of study medication or over-the-counter (OTC) drugs or herbal medicines/food supplement within 7 days or hormonal methods of contraception within 28 days (Depo-Provera must be discontinued at least 6 months) prior to receiving the first dose of study medication.
19. History of difficulty in accessibility of veins in left and right arm.
20. Blood donation (one unit or 450 mL) within the past 3 months before the study.
21. Participation in any clinical study within the past 3 months before the study.
22. Subjects who are unwilling or unable to comply with the lifestyle guidelines described in this protocol.

(\* Depend on decision of principal investigator and/or clinical investigator)

Primary outcomes:
measure: Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)
timeFrame: Blood samples will be collected for PK an pre-dose and at 0.083, 0.167, 0.333, 0.500, 0.670, 0.830, 1.000, 1.330, 1.670, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 8.000, 10.000, 12.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose
measure: Maximal measured plasma concentration (Cmax)
timeFrame: Blood samples will be collected for PK an pre-dose and at 0.083, 0.167, 0.333, 0.500, 0.670, 0.830, 1.000, 1.330, 1.670, 2.000, 2.500, 3.000, 3.500, 4.000, 5.000, 6.000, 8.000, 10.000, 12.000, 16.000, 24.000, 36.000 and 48.000 hours post-dose
Secondary outcomes:
measure: Number of subjects with adverse events
timeFrame: Approximately the day 14 after the last visit
Other outcomes:
Locations:
Study officials:
References: